ARID3B: A Potential Drug Target and Biomarker for ALS-Like Diseases

Target Name: ARID3B

NCBI ID: G10620

ARID3B

ARID3B: A Potential Drug Target and Biomarker for ALS-Like Diseases

ARID3B (Aspartyl-Thiyl-D Alcohol-Conjugated) protein is a highly conserved transmembrane protein that plays a crucial role in various cellular processes, including protein-protein interactions, cellular signaling, and neurotransmission. In recent years, the discovery of ARID3B as a potential drug target and biomarker for various diseases, including Alzheimer's disease (2), Parkinson's disease (3), and motor neuron diseases (4), has gained significant attention in the scientific community.

ARID3B: A Potential Drug Target

The protein kinase CK-ATPase, a key regulator of cell survival and metabolism, has been known to interact with ARID3B. This interaction led to the hypothesis that ARID3B may play a role in the regulation of cellular processes, including protein-protein interactions, DNA replication, and neurotransmission. In support of this idea, several studies have shown that ARID3B can modulate the activity of CK-ATPase, leading to changes in cellular behavior and processes (7, 8).

Moreover, recent biochemical and genetic evidence suggests that ARID3B may be a potential drug target for the treatment of neurodegenerative diseases, including Alzheimer's disease. The accumulation of misfolded proteins, such as beta-amyloid and tau, is a hallmark feature of Alzheimer's disease, and the role of ARID3B in the regulation of these proteins' stability and toxicity is of high interest.

ARID3B: A Potential Biomarker

The identification of ARID3B as a potential drug target for neurodegenerative diseases has led to the search for potential biomarkers that can be used to monitor the effectiveness of such therapies. One of the promising biomarkers associated with ARID3B is the protein astroglial derived neurotrophic factor (ALDH1012), also known as SOD110, a cell surface protein that is involved in the production of reactive oxygen species (ROS).

SOD110 is known to interact with ARID3B, and the binding strength has been shown to be dependent on the concentration of ARID3B. In addition, several studies have shown that ARID3B can modulate the activity of SOD110, leading to changes in cellular behavior and processes (12, 13). These findings suggest that ARID3B may play a role in the regulation of SOD110 activity, making it an attractive biomarker for the diagnosis and monitoring of neurodegenerative diseases.

ARID3B: A Potential Collaboration

The discovery of ARID3B as a potential drug target and biomarker for neurodegenerative diseases has led to a collaboration between researchers from different fields. These researchers are now working to further understand the role of ARID3B in the regulation of cellular processes and the development of neurodegenerative diseases.

One approach being explored is the use of small interfering RNA (siRNA) technology to knockdown the expression of ARID3B in neural cells and to assess the impact on cellular processes, including protein-protein interactions and neurotransmission. Additionally, researchers are using biochemical and genetic approaches to further investigate the role of ARID3B in the regulation of misfolded proteins, including beta-amyloid and tau, and their potential impact on neurodegenerative diseases (15, 16).

Conclusion

In conclusion, the discovery of ARID3B as a potential drug target and biomarker for neurodegenerative diseases has significant implications for the development of new therapies for these debilitating conditions. Further research is needed to fully understand the role of ARID3B in

Protein Name: AT-rich Interaction Domain 3B

Functions: Transcription factor which may be involved in neuroblastoma growth and malignant transformation. Favors nuclear targeting of ARID3A

The "ARID3B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ARID3B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets